olivLaw · US equity research
Aveanna Healthcare Holdings, Inc. AVAH
Services-Home Health Care Services · SIC 8082 · Vertical: Services-Home Health Care Services (SIC 8082)
Aveanna Healthcare Holdings provides home healthcare, mainly private duty nursing for children and adults with complex needs, as a lower-cost alternative to hospitalization. The company grew revenue 13.7% in the second quarter of 2026 and raised its annual guidance, while Medicare and Medicaid reimbursement rules remain a key variable.
At the close of 05 Nov 2026, Aveanna Healthcare Holdings, Inc. (AVAH) stock was 13.67 USD (−3.94% on the day), with market capitalisation 3.0 bn USD, P/E 11.1 on diluted EPS of 1.23 USD over the last 12 months, beta 0.89, 52-week range 6.22–14.38 USD. Latest reported quarter (Q2 2027): revenue of 670.5 m USD (+13.7% YoY), net income of 40.3 m USD (+49.1% YoY), diluted EPS 0.18 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 59.1
- strong (55–70)
- Bollinger (20, 2)
- 11.87 – 13.99
- in the upper half of the band · %B 0.85 · band width 16.4%
- SMA 50 / 200
- 13.11 / 9.32
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.25 / 0.14
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +11.9% | −1.1% | +13.0 pp | — |
| 3 months | +46.8% | −0.5% | +47.3 pp | — |
| 6 months | +97.0% | +4.4% | +92.6 pp | — |
| Year to date | +67.3% | +12.3% | +55.0 pp | — |
| 1 year | +48.4% | +13.5% | +34.9 pp | +5.5% |
| 3 years | +823.6% | +76.4% | +747.2 pp | +0.0% |
| 5 years | +63.5% | +63.7% | −0.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2027 · 04 Jul 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | Q1 '27 | Q2 '27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 509.0 m | 519.9 m | 559.2 m | 589.6 m | 621.9 m | 662.5 m | 647.9 m | 670.5 m |
| Cost of revenue | 349.3 m | 348.2 m | 375.7 m | 378.8 m | 419.1 m | 449.2 m | 442.5 m | 452.0 m |
| Gross profit | 159.7 m | 171.7 m | 183.6 m | 210.8 m | 202.8 m | 213.3 m | 205.4 m | 218.5 m |
| SG&A | 88.2 m | 88.7 m | 91.4 m | 90.1 m | 95.4 m | 97.6 m | 95.8 m | 97.1 m |
| Operating income | 34.0 m | 45.8 m | 51.8 m | 80.0 m | 53.6 m | 71.0 m | 69.3 m | 80.0 m |
| Depreciation & amortisation | 2.6 m | 2.4 m | 2.6 m | 2.6 m | 2.6 m | 2.7 m | 3.0 m | 2.8 m |
| Interest expense | 39.2 m | 38.1 m | 36.3 m | 36.0 m | 35.1 m | 32.6 m | 29.2 m | 27.8 m |
| Pre-tax income | -27.3 m | 26.9 m | 10.1 m | 44.1 m | 13.4 m | 39.2 m | 45.0 m | 56.5 m |
| Income tax | 15.5 m | -2.2 m | 5.0 m | 17.1 m | -647.0 k | -139.5 m | 3.3 m | 16.2 m |
| Net income | -42.8 m | 29.2 m | 5.2 m | 27.0 m | 14.1 m | 178.8 m | 41.7 m | 40.3 m |
| Diluted EPS | -0.22 | 0.15 ≈ | 0.03 | 0.13 | 0.06 | 0.80 ≈ | 0.19 | 0.18 |
| Operating cash flow | 29.4 m ≈ | 13.4 m | -8.6 m | 51.6 m ≈ | 33.2 m ≈ | 49.7 m | 4.3 m | 80.9 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 100 percentile of its own 3-quarter history (min 5.4, median 7.4, max 7.9; quarters with earnings only).
Fiscal years
| Fiscal year | 2019 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | 1.4 bn | 1.5 bn | 1.8 bn | 1.9 bn | 2.0 bn | 2.4 bn |
| Revenue YoY | unavailable | unavailable | +19.6% | +6.0% | +6.8% | unavailable |
| Net income | -76.5 m | -57.1 m | -662.0 m | -134.5 m | -10.9 m | 225.0 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -3.57 | -0.71 | -0.06 | 1.05 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -5.5% | -3.8% | -37.0% | -7.1% | -0.5% | 9.2% |
| Free cash flow | -25.4 m | 101.4 m | -64.4 m | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2026 · 03 Jan 2026
- Cash
- 193.3 m USD
- Financial debt
- 1.3 bn USD
- Net debt
- 1.1 bn USD
- Equity
- 194.5 m USD
- Total assets
- 2.0 bn USD
- Debt / equity
- 6.68x
- Current ratio
- 1.32x
- ROE
- unavailable
- ROA
- 11.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2019 | 2021 | 2022 | 2023 | 2024 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.4 bn | 1.5 bn | 1.8 bn | 1.9 bn | 2.0 bn | 2.4 bn | SEC (XBRL)· 19 Mar 2026verified |
| Cost of revenue | 964.8 m | 1.0 bn | 1.2 bn | 1.3 bn | 1.4 bn | 1.6 bn | SEC (XBRL)· 19 Mar 2026verified |
| Gross profit | 419.3 m | 454.5 m | 553.2 m | 595.4 m | 635.5 m | 810.5 m | SEC (XBRL)· 19 Mar 2026verified |
| SG&A | 227.8 m | 240.9 m | 357.2 m | 361.0 m | 352.8 m | 374.5 m | SEC (XBRL)· 19 Mar 2026verified |
| Operating income | 39.0 m | -3.5 m | -642.3 m | 8.1 m | 139.8 m | 256.5 m | SEC (XBRL)· 19 Mar 2026verified |
| Depreciation & amortisation | 14.3 m | 17.0 m | 21.3 m | 13.8 m | 10.8 m | 10.5 m | SEC (XBRL)· 19 Mar 2026verified |
| EBITDA | 53.3 m ≈ | 13.5 m ≈ | -621.0 m ≈ | 21.9 m ≈ | 150.6 m ≈ | 267.0 m ≈ | SEC (XBRL)· 19 Mar 2026derived |
| Interest expense | 92.3 m | 83.0 m | 107.7 m | 153.2 m | 156.6 m | 140.1 m | SEC (XBRL)· 19 Mar 2026verified |
| Pre-tax income | -75.0 m | -51.7 m | -663.8 m | -139.0 m | 5.1 m | 106.9 m | SEC (XBRL)· 19 Mar 2026verified |
| Income tax | 1.5 m | 5.3 m | -1.8 m | -4.5 m | 16.0 m | -118.1 m | SEC (XBRL)· 19 Mar 2026verified |
| Net income | -76.5 m | -57.1 m | -662.0 m | -134.5 m | -10.9 m | 225.0 m | SEC (XBRL)· 19 Mar 2026verified |
| Diluted EPS | — | — | -3.57 | -0.71 | -0.06 | 1.05 | SEC (XBRL)· 19 Mar 2026verified |
| Weighted average diluted shares | — | — | 185.6 m | 190.0 m | 192.9 m | 215.0 m | SEC (XBRL)· 19 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2019 | 2021 | 2022 | 2023 | 2024 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | — | 137.3 m | 19.2 m | 43.9 m | 84.3 m | 193.3 m | SEC (XBRL)· 19 Mar 2026verified |
| Receivables | — | 172.9 m | 221.2 m | 236.6 m | 265.2 m | 313.4 m | SEC (XBRL)· 19 Mar 2026verified |
| Current assets | — | 340.6 m | 269.8 m | 314.9 m | 392.7 m | 560.2 m | SEC (XBRL)· 19 Mar 2026verified |
| Property, plant & equipment, net | — | 32.7 m | 22.8 m | 20.5 m | 17.4 m | 16.7 m | SEC (XBRL)· 19 Mar 2026verified |
| Goodwill | 1.2 bn | 1.3 bn | 1.2 bn | 1.1 bn | 1.1 bn | 1.1 bn | SEC (XBRL)· 19 Mar 2026verified |
| Intangibles (excl. goodwill) | — | 73.6 m | 95.9 m | 94.0 m | 89.6 m | 92.6 m | SEC (XBRL)· 19 Mar 2026verified |
| Total assets | — | 1.8 bn | 1.7 bn | 1.6 bn | 1.7 bn | 2.0 bn | SEC (XBRL)· 19 Mar 2026verified |
| Short-term debt | — | 9.9 m | 9.2 m | 9.2 m | 9.2 m | 13.3 m | SEC (XBRL)· 19 Mar 2026verified |
| Long-term debt | — | 1.2 bn | 1.3 bn | 1.3 bn | 1.3 bn | 1.3 bn | SEC (XBRL)· 19 Mar 2026verified |
| Current liabilities | — | 260.4 m | 326.5 m | 354.8 m | 402.2 m | 424.5 m | SEC (XBRL)· 19 Mar 2026verified |
| Total liabilities | — | 1.6 bn | 1.7 bn | 1.7 bn | 1.8 bn | 1.8 bn | SEC (XBRL)· 19 Mar 2026verified |
| Equity | 270.2 m † | 265.0 m † | -6.3 m † | -129.6 m † | -123.6 m † | 194.5 m † | SEC (XBRL)· 19 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2019 | 2021 | 2022 | 2023 | 2024 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -8.7 m | 116.6 m | -48.4 m | 22.7 m | 32.6 m | 125.9 m | SEC (XBRL)· 19 Mar 2026verified |
| Capex | 16.6 m | 15.2 m | 16.0 m | — | — | — | SEC (XBRL)· 28 Mar 2022verified |
| Free cash flow | -25.4 m ≈ | 101.4 m ≈ | -64.4 m ≈ | — | — | — | SEC (XBRL)· 16 Mar 2023derived |
| Investing cash flow | -17.8 m | -193.5 m | -25.3 m | -8.8 m | -6.3 m | -22.3 m | SEC (XBRL)· 19 Mar 2026verified |
| Financing cash flow | 21.9 m | 210.9 m | 62.4 m | 10.8 m | 14.0 m | 5.4 m | SEC (XBRL)· 19 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 49 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 3.0 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation44
- Growth72
- Balance sheet9
- Quality93
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 14.06 – 34.52 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDA14.06 – 19.15 (Mid 15.76)3 companies used · median multiple 16.3x · quartiles 15.0x – 18.9xBTSG, CHE, OPCH
- Peers: P/E27.45 – 34.52 (Mid 29.67)4 companies used · median multiple 24.1x · quartiles 22.3x – 28.1xADUS, BTSG, CHE, OPCH
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 49/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 17.3% | 100 (on a fixed band) | 16% |
| Net margin · Quality | 10.6% | 80 (vs peers) | 9% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 8.7% | 72 (on a fixed band) | 13% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 4.2x | 0 (on a fixed band) | 16% |
| Interest coverage · Balance sheet | 2.2x | 11 (on a fixed band) | 9% |
| Current ratio · Balance sheet | 1.2x | 30 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | 11.1x | 86 (on a fixed band) | 16% |
| EV/EBITDA · Valuation | 14.7x | 3 (on a fixed band) | 16% |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet9/100 · 3/3 factors with a value
- Growth· partial72/100 · 1/2 factors with a value
- Quality93/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation44/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Aveanna Healthcare Holdings Inc. (AVAH). Latest full fiscal year: 2026; data up to 2026-07-04.
Figures computed from the financial statements: revenue 2.4 bn USD in 2026; net margin 10.6%; ROE 199.6%; net debt/EBITDA 4.2x.
The estimated value range is 20.76–26.84 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 22.72 USD, the price of 13.67 USD leaves a potential of 66.2% (value / price − 1) and a margin of safety of 39.8% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 49/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth, returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 17.3%
- Net margin: 10.6%
- Revenue CAGR 3Y: 8.7%
- P/E (TTM): 11.1x
- The price is below the estimated value range
What contradicts it
- Net debt / EBITDA: 4.2x
- Interest coverage: 2.2x
- EV/EBITDA: 14.7x
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Home Health Care Services (SIC 8082) · same industry (4-digit SIC) · compared with 5 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| BTSGBrightSpring Health Services, Inc. | 13.1 bn | 35.7 | 20.5% | 2.7% | +28.2% | +82% / unavailable |
| CHEChemed Corporation | 6.9 bn | 25.5 | 29.1% | 10.6% | +4.1% | +22% / −6% |
| OPCHOption Care Health, Inc. | 4.7 bn | 22.7 | 16.0% | 3.7% | +13.0% | +1% / +6% |
| AVAHAveanna Healthcare Holdings Inc. | 3.0 bn | 11.1 | 199.6% | 10.6% | unavailable | +48% / +824% |
| ADUSAddus HomeCare Corp | 2.4 bn | 21.1 | 10.0% | 7.4% | +23.2% | +5% / +45% |
| AHCOAdaptHealth Corp. | 1.0 bn | — | -28.6% | -11.4% | −0.5% | −23% / −13% |
1- and 3-year price returns: for AVAH from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 8.62 Total return -37% · Per year -37% | 15.21 Total return 11% · Per year 11% | 22.87 Total return 67% · Per year 67% |
| 3 years | 9.09 Total return -34% · Per year -13% | 17.97 Total return 31% · Per year 10% | 29.56 Total return 116% · Per year 29% |
| 5 years | 9.58 Total return -30% · Per year -7% | 21.23 Total return 55% · Per year 9% | 38.21 Total return 179% · Per year 23% |
- Exit P/E± 4.49
- Net margin± 3.14
- Annual revenue growth± 2.48
- Annual dilution± 0.26
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Aveanna Healthcare Holdings provides home healthcare, mainly private duty nursing for children and adults with complex needs, as a lower-cost alternative to hospitalization. The company grew revenue 13.7% in the second quarter of 2026 and raised its annual guidance, while Medicare and Medicaid reimbursement rules remain a key variable 123.
SWOT
Strengths
- The platform holds a strong position in pediatric private duty nursing, with close ties to children's hospitals and payers 1.
- Its technology infrastructure and dedicated integration office allow several acquisitions to be pursued at once without disrupting operations 1.
- Revenue growth and the raised 2026 guidance point to solid operating execution across all segments 23.
Weaknesses
- Dependence on Medicare and Medicaid means reimbursement cuts affect results directly 1.
- Gross margin declined in the recent period compared with the prior year, which signals cost pressure from clinical staffing 3.
- High indebtedness and interest costs, partly managed with hedging instruments, limit financial flexibility 3.
Opportunities
- The Family First Homecare acquisition could extend pediatric presence into more states if integration follows plan 1.
- Growing preference for home care and value-based payment models could open new payer contracts 1.
- Expanding HHH and hospice services could diversify revenue if admission volumes hold 1.
Threats
Risks
- Dependence on public reimbursementhigh
Most revenue comes from government programs, and rate changes can materially reduce income 1.
- Medicaid reformhigh
Stricter eligibility and funding reductions could affect PDN service volumes 1.
- Debt and interest costmedium
Total indebtedness is significant, and variable-rate exposure is only partly hedged with financial instruments 3.
- Acquisition integrationmedium
Integrating Family First could encounter operational or staffing difficulties that affect the expected return 1.
- Pressure on clinical staffmedium
Reliance on nurses and qualified personnel can raise costs and limit the ability to recruit 1.
Investment thesis
What would need to be true (bull case)
- Revenue growth and a raised guidance show the model can expand organically and through acquisitions 23.
- Leadership in pediatric home nursing and payer partnerships could support a stable market position 1.
- Demand for home care, which costs less than hospitalization, gives a structural base for growth 1.
What to watch
- Closing of the Family First Homecare acquisition and its effect on PDS revenueQ3 2026
- Delivery against fiscal 2026 revenue and Adjusted EBITDA guidance2026
- Trend in gross margin and clinical staffing costsQ3 2026
- Effects of Medicaid reform and Medicare adjustments on reimbursement2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Aveanna presents itself as a diversified home care platform focused on medically complex, high-cost patients. Its model relies on caregivers, mainly skilled nurses, and on proprietary technology for recruiting, scheduling and clinical documentation 1. Revenue reached 2433.2 million USD in fiscal 2025 1.
The company was incorporated in Delaware in 2016 and has traded on Nasdaq since April 2021, with headquarters in Atlanta, Georgia 1. Its strategy combines organic growth with acquisitions, and an integration office prepares an integration plan before signing 1. In March 2026 Aveanna announced the acquisition of Family First Homecare, a pediatric home care provider, for 175.5 million USD in cash 1.
The company says its partnerships with managed care and government payers, together with its one-stop-shop service model, allow it to staff more cases and maintain stronger hospital referral relationships 1. Management describes these advantages as reinforcing volume and profitability over time 1.
Segments
Market context
The U.S. home care market is fragmented, with many local and regional providers, and the pediatric and complex-care niches have higher entry barriers linked to staffing and payer relationships 1. Demand is supported by the preference of patients and the health system for care at home, which is less costly than hospitalization 1.
Services are funded almost entirely by Medicare, Medicaid and private insurers, so reimbursement levels and public program rules are the decisive factors for margins 1. Recent Medicare payment adjustments and Medicaid reforms directly affect this market 1.
Trends
- Lower Medicare reimbursement for home healthheadwind
CMS final rules for 2026 reduced Medicare rates after an even more restrictive proposal; if reductions repeat, margins in the HHH segment could be compressed 1.
- Medicaid reform under OBBBAheadwind
The One Big Beautiful Bill Act reduces federal Medicaid spending and introduces stricter eligibility conditions, which could shrink the beneficiary pool and PDN revenue 1.
- Rising demand for home caretailwind
The preference for care at home, which is cheaper than hospitalization, supports patient volumes and the company's appeal to hospitals and payers 1.
- Consolidation of managed care payersmixed
Managed care organizations concentrate their networks on fewer providers, which can favor large-scale providers but may also exclude smaller ones 1.
Competitive position
Aveanna faces competition from community home health providers, national, regional and local hospice companies, hospital-based home health agencies and nursing homes 1. Larger competitors may have greater financial and technological resources, and nonprofits can finance investments on tax-advantaged terms 1.
The company's advantage rests on national scale, local density and payer partnerships, which it describes as difficult to replicate 1. In markets without certificate-of-need rules, entry is relatively easy, which keeps competitive pressure high 1.
- Community home health providers
Local organizations competing on staff availability and service quality 1.
- National, regional and local hospice companies
Operators with greater financial and marketing resources active in the HHH segment 1.
- Hospital-based home health agencies
Providers integrated into hospital systems that can take over patients after discharge 1.
- Nonprofit care organizations
Entities that can finance acquisitions and capital spending on tax-advantaged terms unavailable to the company 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Jim Cramer Compares Aveanna Healthcare (AVAH) With Hinge Health (HNGE)Yahoo Finance — News · 18 Sept 2026 · EN
- Aveanna Healthcare Stock Offers Everything Investors Want as Shares Hit New All-Time HighYahoo Finance — News · 28 Aug 2026 · EN
The latest news item in our archive is from 18 Sept 2026; the newest SEC filing is from 02 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report02 Oct 2026Departure or appointment of officers
- Current report24 Aug 2026Other events · Financial statements and exhibits
- Quarterly report13 Aug 2026
- Current report13 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Current report13 Aug 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report07 Aug 2026Departure or appointment of officers
- Current report02 Jun 2026Other events · Financial statements and exhibits
- Current report29 May 2026Shareholder vote
- Current report28 May 2026Other events · Financial statements and exhibits
- Current report15 May 2026Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2026-01-03 · SEC / Aveanna Healthcare Holdings, Inc. · 19 Mar 2026
- [2] Form 10-Q, quarter ended 2026-07-04 · SEC / Aveanna Healthcare Holdings, Inc. · 13 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Aveanna Healthcare Holdings, Inc. · 13 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.